For the year ending 2025-10-31, ANIX had -$27K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-10-31 |
|---|---|
| Net loss | -11,028 |
| Stock option compensation to employees and directors | 3,681 |
| Stock options issued to consultants | 129 |
| Amortization of operating lease right-of-use asset | 36 |
| Amortization of discount on held-to-maturity securities | 143 |
| Receivables | -173 |
| Prepaid expenses and other current assets | -552 |
| Accounts payable | -360 |
| Accrued expenses | -185 |
| Operating lease liability | -28 |
| Net cash used in operating activities | -7,173 |
| Disbursements to acquire short-term investments | 44,360 |
| Proceeds from maturities of short-term investments | 49,226 |
| Net cash provided by investing activities | 4,866 |
| Proceeds from sale of common stock in an at-the-market offering, net of offering expenses of 183 and 168, for the years ended october 31, 2025 and 2024, respectively | 2,378 |
| Proceeds from sale of common stock pursuant to employee stock purchase plan | 7 |
| Net (costs) proceeds from exercise of stock options | -105 |
| Net cash provided by financing activities | 2,280 |
| Net (decrease) increase in cash and cash equivalents | -27 |
| Cash and cash equivalents at beginning of period | 1,271 |
| Cash and cash equivalents at end of period | 1,244 |
Anixa Biosciences Inc (ANIX)
Anixa Biosciences Inc (ANIX)